JiscMail Logo
Email discussion lists for the UK Education and Research communities

Help for ACB-CLIN-CHEM-GEN Archives


ACB-CLIN-CHEM-GEN Archives

ACB-CLIN-CHEM-GEN Archives


ACB-CLIN-CHEM-GEN@JISCMAIL.AC.UK


View:

Message:

[

First

|

Previous

|

Next

|

Last

]

By Topic:

[

First

|

Previous

|

Next

|

Last

]

By Author:

[

First

|

Previous

|

Next

|

Last

]

Font:

Proportional Font

LISTSERV Archives

LISTSERV Archives

ACB-CLIN-CHEM-GEN Home

ACB-CLIN-CHEM-GEN Home

ACB-CLIN-CHEM-GEN  September 2013

ACB-CLIN-CHEM-GEN September 2013

Options

Subscribe or Unsubscribe

Subscribe or Unsubscribe

Log In

Log In

Get Password

Get Password

Subject:

Available positions for early-stage researchers

From:

Paolo Ruggerone <[log in to unmask]>

Reply-To:

Paolo Ruggerone <[log in to unmask]>

Date:

Mon, 30 Sep 2013 17:03:25 +0100

Content-Type:

text/plain

Parts/Attachments:

Parts/Attachments

text/plain (59 lines)

Early-stage researchers – ITN Network Translocation

The network associated with the ITN Project “Translocation” is composed of 10 partners (7 academic institutions and 3 small and medium enterprises, SMEs). Additionally, three Pharmaceutical companies (Basilea Pharmaceutica International, GlaxoSmithKline, and Astrazeneca) will be Associate Members of the project. The Pharmaceutical companies will provide training courses and host secondments, which will complement the comprehensive research, scientific and personal development opportunities offered by the SME and Academic Members. The network is coordinated by the Jacobs University in Bremen (Germany) and seeks to recruit 12 postgraduate students for PhD positions which will last up to 3 years. The network will address the problem of the bacterial resistance by combining several scientific and technology platforms, ranging from electrophysiology, mass spectroscopy, biological assay development and molecular modelling. These platforms are well established within the consortia and most of the members have longstanding common research activities and collaborative programs already in place. Our goal is to better understand the molecular determinants of the rate limiting steps involved in antibiotic transport into bacterial pathogens as well as active compound clearance mechanisms used by bacteria. Addressing these problems is of critical importance in helping to develop new strategies to overcome multi-drug resistance and create better antibiotic treatments in the future.

The recruitment process will be centralised and applicants are invited to apply for one or more of the projects detailed below. Applicants should submit their CV and cover letter to Paolo Ruggerone ([log in to unmask]). The first closing date for receipt of applications will be October 31st, 2013. However, we will consider applications until the posts are filled. Applicants should familiarise themselves with the eligibility rules associated with the Marie Curie ITN programs, particularly with regard to certain restrictions on candidates applying for positions in countries where they have recently resided. Positions will start on January 1st, 2014.

The available positions are the following:

1) Antibiotic translocation, Jacobs University, Bremen (D), responsible: Mathias Winterhalter
Characterization of the influx of antibiotics or efflux pump blockers through porins using electrophysiology and 
complementary techniques.

2) Screening antibiotics on the chip, Nanion Technologies (D) - SME, responsible: Nils Fertig
Screening of antibiotic permeation through porins towards low throughput <100recordings/day. Nanion developed a unique planar patch clamp chip used for the electrophysiological analysis of mammalian cells. Planar bilayer recordings are attractive for investigations of membrane proteins not accessible to patch clamp analysis, like e.g. proteins from organelles or bacteria. This technique offers substantial advantages as compared to traditional patch clamp and BLM recording, in terms of facile handling and improved sensitivity. Particular the enhanced sensitivity will improve the time resolution of the measurements.

3) Pathway modeling, University of Cagliari (I), responsible: Matteo Ceccarelli
The group combined MD simulations with an acceleration scheme to follow the translocation of antibiotics through porins at atomic scale. Multi-scale algorithms extend the simulation time to the range to milliseconds, making it possible to obtain the reactive pathway that antibiotics follow during passive diffusion. Accelerated MD simulations have revealed a putative translocation pathway for penicillins  and fluoroquinolone  through OmpF and porins extracted from resistant strains. Through the associated free energy surface (FES) of this process, affinity sites and activation barriers can be identified.

4) Crystallisation porins 1, University of Newcastle (UK), responsible: Bert Van der Berg
Our goal is to clone, express and purify OmpU and OmpT, the two key OM uptake channels of Vibrio cholerae to give a better overall picture of the structure of a diverse set of porin proteins. In addition we will attempt to co-crystallize these OM channels with substrates, giving a rich body of structural information to help inform computation simulations.

5) Crystallisation porins 2, University of St. Andrews (UK), responsible: Jim Naismith
The group uses x-ray crystallography to study the structures of membrane proteins. We are particularly interested in channels which conduct ions and polar molecules. For example, the crystal structure of OmpC mutants revealed that changes in antibiotic transport were more likely due to changes in the transverse electrostatic field. The group is also pioneering the use of PELDOR spectroscopy to monitor conformational change in integral membrane proteins.

6) Crystallization efflux pumps, Goethe University, Frankfurt am Main (D), responsible: Klaas M. Pos
The RND component AcrB has been intensively studied using biochemical and structural methods. High-resolution structures of wild-type AcrB and several of its single-site variants have been determined via X-ray crystallography. Latest structural data revealed multiple binding sites for drugs simultaneously within the loose and tight  protomer.  Insights into the drug binding sites are key to further studies on how to develop inhibitors of the RND component and are important sources for forthcoming computational analysis on the drug efflux mechanisms.

7) Modelling the assembly of efflux pumps, Jacobs University, Bremen (D), responsible: Ulrich Kleinekathoefer
The computational group has expertise in molecular dynamics simulations applied to  ion and substrate transport through porins but more importantly in modelling TolC and AcrB (in cooperation with the groups from UCA and GUF). It is still an open question how and why TolC and its homologoues assume open conformations upon assembling of the tripartite complex. The group will complement ongoing experimental work using all-atom MD studies. Molecular-level hypotheses by the experimental partners can be tested and new experiments can be suggested. Attention will be devoted to the assembly of the different efflux pump components beyond simple static docking models. 

8) Key residues in RND transporter, University of Cagliari (I), responsible: Paolo Ruggerone
Concerning efflux systems, still unclear are several issues, such as to what extent the functional rotation, i.e., the specific series of sequential conformational changes, is essential for the drug extrusion and whether cooperativity effects are also involved. Thus, molecular details of the mechanism, recognition and uptake for AcrB and MexB require further investigations that will be performed by UCA in collaboration with JUB and GUF. Inhibitors, used in combination with antibiotics, expand the spectrum of antibacterial activity, reverse resistance and dramatically reduce the rates of resistance development, but the molecular details of their action are still elusive. The ‘non-specificity’ of the transporters asks for the role of the pump’s putative affinity in resistance and inhibition. Additionally, insights on possible allosteric sites in the efflux pumps will be gained by extended MD simulations and indicate sites to be targeted by inhibitors.

9) Screening for drug-like compounds which modulate porin function, European ScreeningPort GmbH, Hamburg (D) - SME, responsible: Phil Gribbon
Our overall aim to identify novel compounds capable of modulating antibiotic transport activity in a beneficial manner, therefore creating an opportunity to help better define future adjuvant strategies. Our principle approach is to improve the availability of antibiotics at their site of action by selectively blocking transport protein function. We will quantify isolated efflux systems using the Iongate (Surf2er) and Ionovation (Compact) in- vitro cell free electrophysiology technologies, by characterizing activation via capacitance-based readouts. A screening process, to monitor the ability of compounds to modulate the function of transporter proteins, will be defined and validated. The aim is to develop industrial quality Primary electrophysiological assays with the capacity to process 100’s of compounds per week. Hit compound selection will be supported by high content secondary assays and classical fluorescence efflux measurements in cell based systems. We will work with molecular modelling teams to understand the putative mechanism of interaction of Hit compounds with key candidate proteins.

10) Envelope permeability during infection, University of Basel (CH), responsible: Dirk Bumann
Current whole-cell assays for screening antimicrobials rely on standardized, well-accepted in vitro conditions. Although useful, such conditions may not fully reproduce relevant conditions that pathogens encounter in infected host tissues.  Gram-negative bacteria such as Pseudomonas readily adapt to different conditions by comprehensively remodelling their cell envelope properties such as differential expression of one or more of the some 30 porins, induction of one or more of their ~20 efflux pumps, or modifications to the lipopolysaccharide. This envelope remodelling can substantially affect envelope penetration of antimicrobials. As a consequence, antimicrobials with promising activity under standard in vitro conditions might fail under relevant in vivo conditions because of insufficient penetration or increased expulsion/degradation in that environment.

11) Regulation of porins, University of Marseille-Aix (F), responsible: Jean-Marie Pages
Several specific regulators (e.g. RamA and RamR) play a key role in modulating the membrane permeability via the porin/efflux pump expression and contribute to MDR. In addition, various compounds such as salicylate, imipenem or chloramphenicol are able to induce or select the MDR response. This phenomenon has been observed in vitro by adding drugs to bacterial cultures as well as in clinical settings during antibiotic treatment of infected patients. Regulation of membrane permeability directly affects the intracellular accumulation of antibiotics. 
Our results showed the role of local (acrR, OmpX) or global regulators (MarR, RamR) involved in the emergence of MDR in Enterobacter. AMU currently performs an antibiotic susceptibilities analysis on their collections of clinically important Enterobacteriaceae. Moreover, AMU has recently developed a platform allowing the high throughput determination of the activity of large number of antibacterial agents e.g. last generation ß-lactams, fluoroquinolones, etc on several strains at the same time. We will identify which porins are expressed in resistant and susceptible strains, respectively. The relationships between porins and antibiotics efficiencies will be further explored by a rate-killing approach. In such experiments, the activity of antibiotics is measured as a function of incubation-time on an E. coli strain expressing a selected porin. AMU has developed a gene-fusion assay (omp-lacZ) to follow the expression of outer membrane porins in the presence of various chemicals. This genetic approach will be used to investigate the expression of Enterobacter porin genes. This monitors the kinetics of porin regulation during external stresses. While previous studies prove the control of membrane permeability in large populations of bacterial cells, they miss the response kinetic and the link in the regulation. Here we characterize the dynamics of gene expression. The analysis of regulators under external stresses allowed us to select appropriate regulators and determine its structure and the effect of mutations or chemical effector on their functional structure.


12) TRIC inhibitor, BioVersysAG, Basel (CH) -SME, responsible: M. Gitzinger
BioVersys follows the approach of inhibiting global or local transcriptional regulators of resistance gene expression. Our TRIC (Transcriptional Regulator Inhibiting Compounds) technology platform allows for the identification of target specific, non-cytotoxic and non-antibacterial small molecules that potentiate the activity of antibiotics. The combinatorial application of BioVersys` TRIC adjuvant compounds with existing antibiotics has been shown to allow for killing of even extensively resistant pathogens at clinically relevant doses of the antibiotic. One of our most advanced projects is specifically focusing on inhibition of efflux-mediated resistance via targeting the transcriptional regulator of the respective efflux-gene resistance cluster.

------ACB discussion List Information--------
This is an open discussion list for the academic and clinical community working in clinical biochemistry.
Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content.
ACB Web Site
http://www.acb.org.uk
Green Laboratories Work
http://www.laboratorymedicine.nhs.uk
List Archives
http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html
List Instructions (How to leave etc.)
http://www.jiscmail.ac.uk/

Top of Message | Previous Page | Permalink

JiscMail Tools


RSS Feeds and Sharing


Advanced Options


Archives

March 2024
February 2024
January 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
March 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
September 2019
August 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
2006
2005
2004
2003
2002
2001
2000
1999
1998


JiscMail is a Jisc service.

View our service policies at https://www.jiscmail.ac.uk/policyandsecurity/ and Jisc's privacy policy at https://www.jisc.ac.uk/website/privacy-notice

For help and support help@jisc.ac.uk

Secured by F-Secure Anti-Virus CataList Email List Search Powered by the LISTSERV Email List Manager